AU2016230859A1 - Roneparstat combined therapy of multiple myeloma - Google Patents

Roneparstat combined therapy of multiple myeloma Download PDF

Info

Publication number
AU2016230859A1
AU2016230859A1 AU2016230859A AU2016230859A AU2016230859A1 AU 2016230859 A1 AU2016230859 A1 AU 2016230859A1 AU 2016230859 A AU2016230859 A AU 2016230859A AU 2016230859 A AU2016230859 A AU 2016230859A AU 2016230859 A1 AU2016230859 A1 AU 2016230859A1
Authority
AU
Australia
Prior art keywords
roneparstat
use according
melphalan
kit
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016230859A
Other languages
English (en)
Inventor
Paola BARBIERI
Alessandro NOSEDA
Vishnu PRAKASH C. RAMANI
Ralph D. SANDERSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leadiant Biosciences SA
UAB Research Foundation
Original Assignee
Leadiant Biosciences S A
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadiant Biosciences S A, UAB Research Foundation filed Critical Leadiant Biosciences S A
Publication of AU2016230859A1 publication Critical patent/AU2016230859A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2016230859A 2015-03-06 2016-03-03 Roneparstat combined therapy of multiple myeloma Abandoned AU2016230859A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562129221P 2015-03-06 2015-03-06
US62/129,221 2015-03-06
US201562153899P 2015-04-28 2015-04-28
US62/153,899 2015-04-28
PCT/IB2016/051196 WO2016142814A1 (en) 2015-03-06 2016-03-03 Roneparstat combined therapy of multiple myeloma

Publications (1)

Publication Number Publication Date
AU2016230859A1 true AU2016230859A1 (en) 2017-08-17

Family

ID=55521766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016230859A Abandoned AU2016230859A1 (en) 2015-03-06 2016-03-03 Roneparstat combined therapy of multiple myeloma

Country Status (16)

Country Link
US (1) US10576101B2 (enExample)
EP (2) EP3265075B1 (enExample)
JP (1) JP2018512394A (enExample)
KR (1) KR20170138405A (enExample)
CN (1) CN107645954A (enExample)
AU (1) AU2016230859A1 (enExample)
BR (1) BR112017018869A2 (enExample)
CA (1) CA2978040A1 (enExample)
DK (1) DK3265075T3 (enExample)
ES (1) ES2715556T3 (enExample)
HK (1) HK1245107A1 (enExample)
HU (1) HUE042681T2 (enExample)
MX (1) MX2017011093A (enExample)
PL (1) PL3265075T3 (enExample)
PT (1) PT3265075T (enExample)
WO (1) WO2016142814A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727157D0 (en) 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
SK288335B6 (sk) 2001-09-12 2016-02-02 Sigma-Tau Research Switzerland S.A. Čiastočne alebo úplne N-desulfatovaný, N-reacetylovaný heparín, spôsob jeho prípravy, jeho použitie na prípravu liečiva s inhibičným účinkom na heparanázu, s antiangiogénnym a protizápalovým účinkom a farmaceutický prostriedok s jeho obsahom
US20100009934A1 (en) 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
EP3265075A1 (en) 2018-01-10
CN107645954A (zh) 2018-01-30
HK1245107A1 (zh) 2018-08-24
US20180050061A1 (en) 2018-02-22
HUE042681T2 (hu) 2019-07-29
PL3265075T3 (pl) 2020-10-05
PT3265075T (pt) 2019-03-25
WO2016142814A1 (en) 2016-09-15
DK3265075T3 (en) 2019-04-08
BR112017018869A2 (pt) 2018-04-17
JP2018512394A (ja) 2018-05-17
MX2017011093A (es) 2018-02-19
KR20170138405A (ko) 2017-12-15
CA2978040A1 (en) 2016-09-15
EP3453389A1 (en) 2019-03-13
EP3265075B1 (en) 2018-12-12
ES2715556T3 (es) 2019-06-04
US10576101B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
DK2582683T3 (en) TREATMENT OF Gout and Hyperuricemia
RU2318517C2 (ru) Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
JP5881692B2 (ja) 双極性障害を治療する方法
JP2019052171A (ja) ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2013166765A5 (enExample)
JP2010500371A (ja) 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法
JP2014521658A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
JP2024127990A (ja) アミロイドーシスを処置するための組成物
US20190343851A1 (en) Methods for cancer therapy
KR20240104138A (ko) 니로가세스타트를 사용한 조성물 및 치료
JP2024506825A (ja) Ｓ１ｐ受容体調節剤による処置の方法
EP3265075B1 (en) Roneparstat combined therapy of multiple myeloma
TWI830700B (zh) 以組合療法治療腦瘤之方法
JP2025530190A (ja) アルツハイマー病治療のための免疫療法薬とｓｃｙｌｌｏ－イノシトールとの組み合わせ
JP2019038858A (ja) ペマフィブラートを含有する医薬
US20250381179A1 (en) Chroman-based compounds for treating cancer
Hussar et al. 2020 New Drug Update
WO2024064002A1 (en) Hdac inhibitor oki-179 for the treatment of cancers resulting from a mapk pathway mutation
JP2023509158A (ja) 腫瘍治療の医薬組み合わせとその使用
Naunton DRUGSCAN: INTERNAL MEDICINE.

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period